KYTX

1.99

6.99% 0.13

Handel nachbörslich: 1.99

Kyverna Therapeutics Inc (KYTX)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$1.86

Offen:

$1.82

24-Stunden-Volumen:

263.62K

Relative Volume:

0.78

Marktkapitalisierung:

$96.38M

Einnahmen:

Nettoeinkommen (Verlust:

$-110.66M

KGV:

-0.6427

EPS:

-3.0963

Netto-Cashflow:

$-97.76M

1W Leistung:

-10.76%

1M Leistung:

-16.39%

6M Leistung:

-61.73%

1J Leistung:

-89.07%

1-Tages-Spanne:

$1.82

$2.05

1-Wochen-Bereich:

$1.78

$2.2556

52-Wochen-Spanne:

$1.78

$19.67

Kyverna Therapeutics Inc Stock (KYTX) Company Profile

Firmenname

Kyverna Therapeutics Inc

Sektor

Healthcare (1182)

Branche

Biotechnology (677)

Telefon

(510) 626-8331

Adresse

5980 HORTON STREET, EMERYVILLE

Mitarbeiter

119

Twitter

Nächster Verdiensttermin

Neueste SEC-Einreichungen

KYTX's Discussions on Twitter

Vergleichen Sie KYTX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
KYTX Kyverna Therapeutics Inc	1.99	96.38M	0	-110.66M	-97.76M	-3.0963
VRTX Vertex Pharmaceuticals Inc	477.52	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	561.49	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	595.70	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	232.75	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	229.22	26.16B	3.81B	-644.79M	-669.77M	-6.24

Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-10-10	Eingeleitet	UBS	Buy
2024-10-09	Eingeleitet	Rodman & Renshaw	Buy
2024-07-03	Eingeleitet	H.C. Wainwright	Neutral
2024-03-04	Eingeleitet	JP Morgan	Overweight
2024-03-04	Eingeleitet	Leerink Partners	Outperform
2024-03-04	Eingeleitet	Morgan Stanley	Overweight
2024-03-04	Eingeleitet	Wells Fargo	Overweight

Alle ansehen

Kyverna Therapeutics Inc Aktie (KYTX) Neueste Nachrichten

Apr 20, 2025

JPMorgan Chase & Co. Sells 220,915 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat

Apr 20, 2025

Gilead Sciences Inc. Acquires New Position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat

Apr 20, 2025

Apr 19, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 19, 2025

Apr 18, 2025

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Sold by Franklin Resources Inc. - MarketBeat

Apr 18, 2025

Apr 17, 2025

Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode - Bluefield Daily Telegraph

Apr 17, 2025

Notice to Long-Term Shareholders of Kyverna Therapeutics, - GlobeNewswire

Apr 17, 2025

Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode Electronics, Inc. (NYSE: MEI); ModivCare, Inc. (NASDAQ: MODV); and Monolithic Power Systems, Inc. (NASDAQ: MPWR)Grabar Law Office Is Investigating Claims - TradingView

Apr 17, 2025

Apr 16, 2025

Investigation announced for Long-Term Investors in shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) - openPR.com

Apr 16, 2025

Apr 15, 2025

Robbins LLP Reminds Kyverna Therapeutics, Inc. Investors of the Pending Securities Fraud Class Action Against KYTX - marketscreener.com

Apr 15, 2025

Kyverna Therapeutics Files For Offering Of Up To $50 Mln Common Stock From Time To TimeSEC Filing - marketscreener.com

Apr 15, 2025

Apr 11, 2025

HC Wainwright Has Negative Outlook for KYTX Q1 Earnings - MarketBeat

Apr 11, 2025

Apr 08, 2025

HC Wainwright Cuts Kyverna Therapeutics (NASDAQ:KYTX) Price Target to $4.00 - MarketBeat

Apr 08, 2025

Apr 07, 2025

KYTX stock plunges to 52-week low, touches $1.85 amid market rout - Investing.com Australia

Apr 07, 2025

KYTX stock plunges to 52-week low, touches $1.85 amid market rout By Investing.com - Investing.com South Africa

Apr 07, 2025

Apr 05, 2025

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Average Recommendation of "Buy" by Analysts - MarketBeat

Apr 05, 2025

Morgan Stanley Has Lowered Expectations for Kyverna Therapeutics (NASDAQ:KYTX) Stock Price - MarketBeat

Apr 05, 2025

Apr 03, 2025

Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025KYTX - ACCESS Newswire

Apr 03, 2025

H.C. Wainwright cuts Kyverna Therapeutics price target to $4 - Investing.com Australia

Apr 03, 2025

KYTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 03, 2025

KYTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 03, 2025

H.C. Wainwright cuts Kyverna Therapeutics price target to $4 By Investing.com - Investing.com Canada

Apr 03, 2025

Apr 01, 2025

Kyverna Therapeutics price target lowered to $20 from $40 at Morgan Stanley - TipRanks

Apr 01, 2025

Mar 31, 2025

ALERT: Grabar Law Office Investigates Claims for Long-Term Shareholders of Holley Inc. (NYSE: HLLY); Integra Lifesciences Holdings Corporation (NASDAQ: IART); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); and Virtu Financial, Inc. (NASDAQ: VIRT) - GlobeNewswire

Mar 31, 2025

Kyverna Therapeutics Advances CAR T-Cell Therapy Trials - MSN

Mar 31, 2025

Kyverna Therapeutics price target lowered to $12 from $13 at UBS - MSN

Mar 31, 2025

Kyverna Therapeutics (NASDAQ:KYTX) Announces Quarterly Earnings Results - MarketBeat

Mar 31, 2025

Mar 30, 2025

KYVERNA THERAPEUTICS Earnings Preview: Recent $KYTX Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 30, 2025

Mar 28, 2025

KYTX stock touches 52-week low at $2.2 amid sharp annual decline - Investing.com

Mar 28, 2025

Kyverna Therapeutics inks sales agreement with Jefferies By Investing.com - Investing.com Canada

Mar 28, 2025

Mar 27, 2025